MedTrace Logo

A Single-Dose Study of MT-201 and Concomitant Infliximab in Healthy Participants

NCT07776782 · Status: RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 25

Last updated 2026-08-21

No results posted yet for this study

Summary

A Phase 1, Open-Label, Single-Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of MT-201 Administered with Concomitant Infliximab in Healthy Participants

Conditions

  • Healthy Volunteer

Interventions

DRUG

MT-201

MT-201 and Infliximab

Sponsors & Collaborators

  • Mirador Therapeutics, Inc.

    lead INDUSTRY

Study Design

Allocation
NA
Purpose
OTHER
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
19 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2026-07-16
Primary Completion
2026-11-12
Completion
2026-11-12
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07776782 on ClinicalTrials.gov